Roche secured rights to Hanmi Pharmaceutical’s obesity drug candidate designed to increase muscle mass while reducing fat, the company disclosed via a deal reported in industry coverage. Roche will pay $190 million upfront, with total consideration potentially reaching $2.3 billion as the parties develop and commercialize the therapy. The asset activates a receptor in skeletal muscle and targets a different mechanism than Roche’s other obesity pipeline entries. Terms exclude South Korea, where Hanmi is based, and outline global development responsibilities across the licensed territory. The agreement adds to Roche’s recent pattern of obesity partnerships, but it also signals an emphasis on differentiating beyond incretin biology by pursuing lean-mass preservation alongside weight loss.